US7667009B2 - Method for purifying modified major mite allergen - Google Patents

Method for purifying modified major mite allergen Download PDF

Info

Publication number
US7667009B2
US7667009B2 US10/555,883 US55588304A US7667009B2 US 7667009 B2 US7667009 B2 US 7667009B2 US 55588304 A US55588304 A US 55588304A US 7667009 B2 US7667009 B2 US 7667009B2
Authority
US
United States
Prior art keywords
mite allergen
major mite
modified major
modified
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/555,883
Other languages
English (en)
Other versions
US20080113424A1 (en
Inventor
Satoshi Koyanagi
Kenjiro Kawatsu
Toshio Murakami
Yoshinobu Miyatsu
Toshihiro Maeda
Hiroshi Mizokami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Assigned to JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE reassignment JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAWATSU, KENJIRO, KOYANAGI, SATOSHI, MAEDA, TOSHIHIRO, MIYATSU, YOSHINOBU, MIZOKAMI, HIROSHI, MURAKAMI, TOSHIO
Publication of US20080113424A1 publication Critical patent/US20080113424A1/en
Application granted granted Critical
Publication of US7667009B2 publication Critical patent/US7667009B2/en
Assigned to THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE reassignment THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to a method for purifying a modified major mite allergen obtained by the genetic recombination technique using E. coli as a host. More specifically, the present invention relates to a method for purifying a modified major mite allergen comprising steps: (1) washing and recovering inclusion bodies containing a modified major mite allergen with MF membrane; (2) dissolving/refolding of said inclusion bodies; (3) treatment with ultrafiltration membrane; (4) treatment with an anion exchanger to recover non-adsorbed fractions; (5) treatment with a hydrophobic gel to recover adsorbed fractions; and (6) treatment with an anion exchanger to recover adsorbed fractions, and a highly purified modified major allergen obtained by said method for purification.
  • an anti-allergic or anti-histaminic agent is used in general.
  • This therapy is unable to radically cure allergic diseases.
  • Hyposensitization where causative antigens of allergic diseases are injected is believed to be a sole measure for radical cure of allergic diseases. Hyposensitization is performed by injecting to a patient suffering from allergic diseases a small amount of allergens causative for said allergic diseases so that allergic reactions within the living body might disappear. Its efficacy is more than 70%.
  • Sole mite allergen preparations currently used are house dust allergen preparations, which are prepared by the process of extracting allergens from house dust.
  • the mite allergen preparations prepared by said process thus also contain a variety of antigens such as e.g. mould or bacteria in addition to mite thereby not to allow for unambiguously defining their biological activity (titer).
  • antigens such as e.g. mould or bacteria in addition to mite thereby not to allow for unambiguously defining their biological activity (titer).
  • antigens such as e.g. mould or bacteria
  • Allergen preparations are mainly administered subcutaneously for immune induction. If allergen preparations are contaminated with impurities, however, the living body receiving said preparations will possibly induce an immune response to the undesired impurities to thereby establish sensitization thereto. Thus, there is possibility that allergy to impurities is newly induced to cause serious adverse side effects. Accordingly, to ensure that allergen preparations are safe, highly purified preparations need be provided.
  • allergen preparations are highly purified, there is still a risk that administering the preparations causes anaphylactic shock.
  • type I allergy typically anaphylactic shock
  • administration of allergens always involves some risk of causing anaphylactic shock.
  • modified major mite allergen A modified type of a major mite allergen (hereinafter also referred to as “modified major mite allergen”) has been prepared using the genetic recombination technique wherein a steric structure of mite allergen is partly destructed so as to reduce its binding to IgE antibody (e.g. Japanese Patent Publication No. 253851/1994 (Japanese Patent Application No. 139793/1993); incorporated herein by reference).
  • This modified major mite allergen resulting from replacement of the cysteine residue in major mite allergen Der f 2 with the serine residue, is expected to be useful as a medicament for therapy of allergy by safely inducing hyposensitization without causing anaphylactic shock.
  • major mite allergens produced by the genetic engineering process on an industrial level are purified to a pharmaceutical grade.
  • a recombinant major mite allergen Der f 2 has been prepared by transforming prokaryotes or eukaryotes with an expression vector comprising a gene encoding Der f 2, culturing the transformants and purifying Der f 2 from the culture.
  • purification from culture is performed by ion exchange chromatography and gel filtration chromatography.
  • the thus purified Der f 2 has purity of merely a reagent grade.
  • refolding of the modified mite allergen is performed by dialysis and hence treatment in a large quantity is difficult.
  • An object of the present invention is to provide a method for purifying a modified major mite allergen produced by the genetic engineering process to a pharmaceutical grade.
  • Another object of the present invention is to provide a modified major mite allergen of high purity that is obtained by the method for purification of the present invention and does not comprise contaminants such as host-derived components.
  • a modified major mite allergen may efficiently be purified from culture of host cells producing the modified major mite allergen by the steps: (1) washing and recovering inclusion bodies containing a modified major mite allergen obtained by the genetic engineering process with MF membrane; (2) dissolving said inclusion bodies followed by refolding; (3) concentrating a solution containing the modified major mite allergen with simultaneous removal of low molecular weight components with ultrafiltration membrane; (4) recovering the modified major mite allergen in non-adsorbed fractions with a weak anion exchanger; (5) recovering the modified major mite allergen in adsorbed fractions with a hydrophobic gel; and (6) recovering the modified major mite allergen in adsorbed fractions with a strong anion exchanger, to thereby complete the present invention.
  • the present invention relates to a method for purifying a modified major mite allergen obtained by the genetic recombination technique, which comprises the purification steps:
  • the present invention provides the method for purification as described above, which comprises the purification steps:
  • the present invention further relates to a purified modified major mite allergen obtained in accordance with the method for purification as described above.
  • a modified major mite allergen obtained by the genetic recombination technique is a modified major mite allergen Der f 2 wherein both the cysteine residues at 8-position and 119-position in Der f 2 are replaced with serine residues
  • the present invention relates to the modified major mite allergen Der f 2 obtained by the method for purification as described above as well as a composition comprising said modified major mite allergen as a major component, said modified major mite allergen Der f 2 having a molecular weight of about 15 kD and isoelectric point of pI 6.6 to 7.2 and being characterized by the following properties:
  • An endotoxin content of a solution containing 500 ⁇ g/ml of the modified major mite allergen is 0.25 EU/ml or less; and more specifically being characterized by the following properties:
  • An endotoxin content of a solution containing 500 ⁇ g/ml of the modified major mite allergen is from 0.002 to 0.25 EU/ml.
  • a modified major mite allergen obtained by the genetic engineering process may be purified efficiently and in a large quantity.
  • the method of the present invention is suitable for industrial production of the modified major mite allergen and allows for stably providing allergen preparations containing a single modified major mite allergen.
  • purity of the desired modified major mite allergen may effectively be increased.
  • a modified major mite allergen obtained by the genetic recombination technique is a modified major mite allergen Der f 2 wherein both the cysteine residues at 8-position and 119-position in Der f 2 are replaced with serine residues
  • said modified major mite allergen Der f 2 having reduced binding to IgE antibody due to partial destruction of its steric structure unlike native major mite allergens
  • purification of said modified major mite allergen by the method in accordance with the present invention allows for provision of modified major mite allergen preparations with reduced risk of causing anaphylactic shock.
  • a modified major mite allergen of high purity may be provided that has the following properties: (1) a single band in SDS-PAGE analysis; (2) a content of contaminating proteins from a host that is 0.1% or less; (3) a content of a polymer of the modified major mite allergen that is less than a detection limit; (4) a content of the modified major mite allergen with distinct steric structure that is 10% or less; and (5) an endotoxin content of a solution containing 500 ⁇ g/ml of the modified major mite allergen that is less than 0.25 EU/ml, a quality standard for water for injection (Japanese Pharmacopoeia, 14th edition).
  • host-derived contaminants may substantially be excluded so as to obviate serious adverse side effects due to said contaminants and hence safe modified major mite allergen preparations may be provided.
  • FIG. 1 shows construction of an expression vector pWU11-C8/119S.
  • FIG. 2 shows a growth curve of cells while fermenter culture.
  • FIG. 3 shows results of SDS-polyacrylamide gel electrophoresis of a sonicate of recombinant E. coli cells proliferated in a fermenter culture, a sampling of which was performed with passage of time, in which Lane 1: before shifting to 37° C.; Lane 2: 1 hour after the temperature shifting to 37° C.; Lane 3: 3 hours after the temperature shifting; Lane 4: 5 hours after the temperature shifting; Lane 5: 7 hours after the temperature shifting; Lane 6: 9 hours after the temperature shifting; and Lane 7: 12 hours after the temperature shifting.
  • FIG. 4 shows results of Western blot analysis using anti-Der f 2 monoclonal antibody in which Lane 1: non-reductive treatment of a purified modified major mite allergen; and Lane 2: reductive treatment of a purified modified major mite allergen.
  • FIG. 5 shows results of SDS-polyacrylamide gel electrophoresis of a modified major mite allergen at each purification step in which Lane 1: refolding; Lane 2: weak anion exchange chromatography; and Lane 3: purified modified major mite allergen.
  • FIG. 6 shows results of SDS-polyacrylamide gel electrophoresis of a purified modified major mite allergen in which Lane 1: non-reductive treatment of a purified modified major mite allergen; and Lane 2: reductive treatment of a purified modified major mite allergen.
  • FIG. 7 shows a chromatographic pattern obtained by gel filtration HPLC analysis of a purified modified major mite allergen.
  • FIG. 8 shows a chromatographic pattern obtained by reversed phase HPLC analysis of a purified modified major mite allergen.
  • FIG. 9 shows results of isoelectric focusing of purified modified major mite allergens (3 lots) in which Lane 1: SF-01; Lane 2: FP-020; and Lane 3: FP-021.
  • FIG. 10 shows results of SDS-polyacrylamide gel electrophoresis of the conventional purified Der f 2 (Asahi Beer Pharmaceuticals) and the purified modified major mite allergen of the present invention in which Lane 1: Der f 2; Lane 2: a modified major mite allergen FP-020; and Lane 3: a modified major mite allergen FP-021.
  • the method for purification of the present invention comprises the steps: (1) washing and recovering inclusion bodies containing a modified major mite allergen obtained by the genetic engineering process with MF membrane; (2) dissolving said inclusion bodies followed by refolding; (3) concentrating a solution containing the modified major mite allergen with simultaneous removal of low molecular weight components with ultrafiltration membrane; (4) recovering the modified major mite allergen in non-adsorbed fractions with an anion exchanger; (5) recovering the modified major mite allergen in adsorbed fractions with a hydrophobic gel; and (6) recovering the modified major mite allergen in adsorbed fractions with an anion exchanger.
  • a modified major mite allergen obtained by the genetic recombination technique to be purified by the method for purification according to the present invention may include those prepared by using the major mite allergen genes identified hitherto such as Der f 2 and Der p 2.
  • the major mite allergens Der f 2 and Der p 2 share homology of 80% or more at an overall amino acid sequence level (Chua K. Y., Int. Arch. Allergy Appl. Immunol. 91(2), 118-123 (1990)) and have the S—S bond at the identical position.
  • a modified major mite allergen of interest may be obtained from a nucleic acid fragment containing any of these major mite allergen genes by partially altering their nucleotide sequences.
  • a modified major mite allergen that may be used in the method of the present invention includes for instance a modified major mite allergen Der f 2 wherein both the cysteine residues at 8-position and 119-position in Der f 2 are replaced with serine residues as described in Japanese Patent Publication No. 253851/1994.
  • any other modified major mite allergens may be used wherein their binding to IgE is reduced through modification of their steric structure.
  • a major mite allergen gene as well as a modified major mite allergen gene wherein replacement is made in a portion of its nucleotide sequence may be prepared using as a starting material mRNAs or genomic DNAs extracted from mites in accordance with the common genetic recombination technique as described by Sambrook (Molecular Cloning, A Laboratory Manual Second Ed., Cold Spring Harbor Laboratory Press, N.Y., 1989).
  • kits may be used for extraction of RNAs.
  • reagents such as TRIzol reagent (Invitrogen), ISOGEN (NIPPON GENE CO., LTD.), and StrataPrep Total RNA Purification Kit (TOYOBO) may be used;
  • kits such as mRNA Purification Kit (Amersham Bioscience), Poly(A) Quick mRNA Isolation Kit (TOYOBO), and mRNA Separator Kit (Clontech) may be used; for conversion into cDNAs, SuperScript plasmid system for cDNA synthesis and plasmid cloning (Invitrogen), cDNA Synthesis Kit (TAKARA SHUZO CO., LTD.), SMART PCR cDNA Synthesis & Library Construction Kits (Clontech), Directionary cDNA Library Construction systems (Novagen Inc.) may be used.
  • a modified major mite allergen gene may be obtained by preparing a plasmid bearing cDNA of a modified major mite allergen and performing PCR using said plasmid as a template in accordance with the method described in Japanese Patent Publication No. 253851/1994.
  • a modified major mite allergen may be produced by introducing the modified major mite allergen gene into a suitable host including, for instance, an animal cell, a plant cell, an insect cell and a microorganism such as E. coli , yeast and Bacillus subtilis . It may also be produced by various animals, so-called animal factory.
  • a suitable host including, for instance, an animal cell, a plant cell, an insect cell and a microorganism such as E. coli , yeast and Bacillus subtilis . It may also be produced by various animals, so-called animal factory.
  • a material containing a modified major mite allergen for use in the present invention may be any material that is prepared by the genetic engineering process and include those known in the art as published in literatures and ones that will be developed in future, including, for instance, a culture of the host as described above producing a modified major mite allergen and a body fluid or secretion from various recombinant animals.
  • a culture of E. coli producing a modified major mite allergen may be used.
  • a culture of E. coli producing a modified major mite allergen may be used wherein expression is induced without an inducer such as indoleacetic acid (IAA) or isopropyl-1-thio- ⁇ -D-galactopyranoside (IPTG).
  • IAA indoleacetic acid
  • IPTG isopropyl-1-thio- ⁇ -D-galactopyranoside
  • a culture containing a modified major mite allergen but not containing an inducer may be obtained for instance by the method as described in Japanese Patent Application No. 2003-58992.
  • a modified major mite allergen gene is incorporated into an expression plasmid comprising a tryptophan promoter and a replication origin from pUC and E. coli is then transformed with the expression plasmid to prepare E. coli producing a modified major mite allergen and a glycerol stock thereof.
  • E. coli producing a modified major mite allergen and a glycerol stock thereof.
  • two-step culture is performed. Firstly, culture is performed at low temperature (25 to 32° C.) so that the cells are sufficiently proliferated. Next, culture temperature is shifted to high temperature (37 to 38° C.) to allow for expression of a modified major mite allergen.
  • Such a two-step culture will enable obtaining a culture containing a modified major mite allergen but not containing an inducer.
  • a term of culture may vary depending on a culture temperature and a scale of production of a major mite allergen.
  • Culture at low temperature may be continued until the recombinant E. coli cells are proliferated to the median of a logarithmic growth phase.
  • Culture at high temperature may be continued until an expression level of a major mite allergen reached its peak.
  • 10 ml of the recombinant E. coli (pWU11-C8/119S/HB101) glycerol stock obtained in Example 1 is inoculated to about 1 L of culture medium.
  • the cells are then inoculated to 200 to 300 L of culture medium for culture at 25° C. for 12 to 17 hours.
  • the cells are cultured at 37° C. for 8 to 16 hours to produce about 7 to 10 g/L of inclusion bodies as a wet weight containing a modified major mite allergen.
  • a culture is initially concentrated with MF membrane (ASAHIKASEI) so as to recover cells.
  • MF membrane as used herein may preferably have a size of 0.1 to 0.25 ⁇ m.
  • Recovered cells are disrupted in an appropriate way to release inclusion bodies containing a modified major mite allergen out of the cells.
  • Cells may be disrupted by any means such as lysing cells with e.g. a chemical substance, a surfactant or an enzyme or physical treatment with French Press or sonication. Any of these treatments may be combined together so that the cells are more efficiently disrupted.
  • the cells recovered by MF membrane are diluted and concentrated with deionized water to remove the remaining culture components and metabolites from the cells and then added with an appropriate buffer and lysozyme.
  • a buffer as used herein may be any buffer that exerts a buffer capacity at a pH range where lysozyme may act (7.5 to 9) such as Tris buffer.
  • a concentration of a buffer may be in such a range that a usual buffer is commonly used (10 to 50 mM). Lysozyme may be used at a concentration of 0.3 to 1.0 g/L.
  • Inclusion bodies may be recovered as a precipitate by centrifugation of a concentrate containing the inclusion bodies
  • the recovered inclusion bodies are then dissolved in a solution containing a reducing agent and a denaturing agent.
  • a reducing agent as used herein, cysteine, glutathione, dithiothreitol and 2-mercaptoethanol may be used. Any of these reducing agents may also be used in combination.
  • a reducing agent may be used at a concentration of 10 to 100 mM, preferably 10 to 50 mM, although it may vary depending on an amount of the inclusion bodies to be dissolved.
  • urea and guanidine hydrochloride may be used, preferably urea.
  • Urea and guanidine hydrochloride may be used at a concentration of 4 to 8 M and 2 to 6 M, respectively.
  • a buffer at pH 7 to 11, preferably pH 8 to 9 is used.
  • a buffer as used herein may be any buffer that exerts a buffer capacity at the pH range as described above such as phosphate buffer, Tris buffer, glycine buffer, carbonate buffer and the like, preferably the one as described in (i) recovery of inclusion bodies above.
  • the inclusion bodies are dissolved in Tris buffer at pH 8.5 containing 20 mM cysteine and 8 M urea.
  • a temperature at which the inclusion bodies are dissolved may be any temperature that is 40° C. or less.
  • a dissolution time may be adjusted while observing a state of dissolution of the inclusion bodies and the mixture is typically stirred for 30 minutes to 1 hour.
  • a reducing agent and an oxidizing agent as used herein include cysteine and cystine, respectively.
  • Cysteine and cystine may be used in a concentration of 1 mM to 10 mM and 0.1 mM to 1 mM, respectively.
  • Cystine may preferably be used at 1/10 amount relative to cysteine.
  • a type and a concentration of a buffer used for refolding may be the same as those used for dissolving the inclusion bodies.
  • a buffer may be used at pH 7.5 to 9. Specifically, 20 mM Tris buffer at pH 8.5 containing 3 mM cysteine and 0.3 mM cystine is used for refolding by diluting or removing the denaturing agent. For removal of the denaturing agent, dialysis, gel filtration and the like are used.
  • a temperature at which the refolding is performed may be any temperature that is room temperature or less. Refolding may be performed by letting the solution left to stand for 1 to 7 days, preferably for 3 to 4 days.
  • the refolding reaction may be quenched by adding an acidic buffer such as acetic acid or hydrochloric acid so as to adjust the pH of the reaction solution to neutrality. Specifically, the refolding reaction is quenched by titration of the reaction solution to pH 7 with 30% acetic acid.
  • an acidic buffer such as acetic acid or hydrochloric acid
  • the solution containing a modified major mite allergen is subject to treatment with ultrafiltration membrane of fractionation M. W. of 6,000 to 10,000 for concentration and removal of low molecular weight components.
  • ultrafiltration membrane of fractionation M. W. of 6,000 to 10,000 for concentration and removal of low molecular weight components.
  • sodium chloride at a final concentration of 30 to 100 mM and the mixture is adjusted to pH 8 to 9 with an alkaline solution. Precipitates formed may be removed with a filter of ⁇ 0.45 ⁇ m.
  • sodium chloride at a final concentration of 50 mM and the mixture is adjusted to pH 8.5 with 5N sodium hydroxide solution.
  • the ultrafiltration treatment may be performed at room temperature or less.
  • the obtained solution containing a modified major mite allergen is subject to the following purification process.
  • an anion exchanger includes diethylaminoethyl (DEAE) type and quaternary aminoethyl (QAE) type.
  • DEAE type includes DEAE-Agarose (product name: DEAE-Sepharose, Amersham), DEAE-Dextran (product name: DEAE-Sephadex, Amersham), DEAE-Polyvinyl (product name: DEAE-TOYOPEARL, Tosoh Corporation) and the like.
  • QAE type includes QAE-Agarose (product name: QAE-Sepharose, Amersham), QAE-polyvinyl (product name: QAE-TOYOPEARL, Tosoh Corporation) and the like.
  • any carrier material may be used but, as for the functional groups, a weak anion exchanger may preferably be used.
  • Any type of a buffer may be used for the anion exchange process but pH of the buffer when a modified major mite allergen is contacted with the column may be in a range of 7 to 10, preferably of pH 8 to 9.
  • a salt concentration may be used in a range of 0.03 to 0.1M, preferably 30 to 60 mM. This purification process removes most of contaminating proteins.
  • the non-adsorbed fractions obtained by treatment with the anion exchanger as described above are contacted with a hydrophobic column, in which a buffer is exchanged with a buffer containing sodium chloride and the column is equilibrated with said buffer, to let a modified major mite allergen adsorbed to the column.
  • a concentration of sodium chloride may be in a range of 2 to 3 M, preferably 3 M.
  • a buffer as used herein may be any type of a buffer at a concentration of 5 to 50 mM, preferably 10 to 20 mM, at pH of 7 to 8.
  • An example of a hydrophobic gel includes a phenyl type, a butyl type, an octyl type, and the like.
  • a carrier material includes Agarose (Amersham), Dextran (Amersham), Polyvinyl (Tosoh Corporation), and the like. In this purification process, any carrier material may be used but, as for the functional groups, a butyl type may preferably be used.
  • a modified major mite allergen is eluted from the hydrophobic column by decreasing a salt concentration.
  • a salt concentration may be decreased by any means such as using a concentration gradient or decreasing a salt concentration stepwise.
  • a chemical substance used for changing a salt concentration includes ammonium sulfate, ammonium acetate, ammonium chloride, ammonium nitrate, potassium acetate, potassium chloride, sodium acetate, calcium chloride, magnesium chloride, etc., any of which may be used.
  • stepwise procedure may preferably be used.
  • a salt concentration while elution is 0 to 1 M, preferably 0 M.
  • a series of column procedures of hydrophobic chromatographic treatment may preferably be performed at 5 to 10° C.
  • the non-adsorbed fractions obtained by treatment with the hydrophobic column as described above are contacted with an anion exchanger column, in which a buffer is exchanged with a buffer containing urea and the column is equilibrated with said buffer, to let a modified major mite allergen adsorbed to the column.
  • Urea contained in the buffer inhibits coagulation of a modified major mite allergen.
  • a concentration of urea may be in a range of 0.5 to 5 M, preferably 1 to 3 M.
  • a buffer as used herein may be any type of a buffer at a concentration of 5 to 50 mM, preferably 10 to 20 mM, at pH of 8 to 10, preferably 8.5 to 9.5. In this purification process as well, any carrier material may be used but, as for the functional groups, a strong anion exchanger may preferably be used.
  • a modified major mite allergen is eluted from the anion, exchanger column by increasing a salt concentration.
  • a salt concentration may be increased by any means such as using a concentration gradient or increasing a salt concentration stepwise.
  • a chemical substance used for changing a salt concentration may include sodium chloride, potassium chloride, calcium chloride, magnesium chloride, etc., any of which may be used.
  • a concentration gradient may be used.
  • a concentration gradient may be prepared by dissolving sodium chloride in the same buffer as used for equilibrium of the column.
  • a salt concentration while elution is 0 to 0.5 M, preferably 0 to 0.1 M.
  • a series of column procedures of treatment with an anion exchanger may be performed at 5 to 10° C.
  • the obtained solution containing a modified major mite allergen after being dialyzed to PBS and aseptically filtered through a filter of ⁇ 0.22 ⁇ m, is stored for use as a modified major mite allergen.
  • Property of a modified major mite allergen at each purification step or after completion of all the purification steps may be elucidated by the techniques routinely used for protein analysis including, for instance, EIA and Western blot with a specific antibody, SDS-polyacrylamide gel electrophoresis (SDS-PAGE) under reductive and non-reductive conditions, high performance liquid chromatography (HPLC), endotoxin test, measurement of absorbance, isoelectric focusing, and the like.
  • a purified modified major mite allergen obtained by the process for purification in accordance with the present invention in case that a modified major mite allergen obtained by the genetic recombination technique is a modified major mite allergen Der f 2 wherein both the cysteine residues at 8-position and 119-position in Der f 2 are replaced with serine residues, has a molecular weight of about 15 kD and isoelectric point of pI 6.6 to 7.2 and is obtained as a recombinant protein of high purity characterized by the following properties: (1) a single band in SDS-PAGE analysis; (2) a content of contaminating proteins from a host that is 0.1% or less; (3) a content of a polymer of the modified major mite allergen that is less than a detection limit; (4) a content of the modified major mite allergen with distinct steric structure that is 10% or less; and (5) an endotoxin content of a solution containing 500 ⁇ g/ml of the modified major mite allergen that is
  • the obtained purified modified major mite allergen may be formulated into pharmaceutical preparations by addition of commonly used additives such as e.g. a stabilizing agent, a surfactant, or a buffer, aseptic filtration, filling, lyophilization, and the like.
  • a modified major mite allergen like a mite allergen extract or a house dust extract, may be used as clinical preparations for therapy of allergic diseases in the form of injections or dosage forms for transmucous administration (intranasal, oral, sublingual).
  • a modified major mite allergen obtained by the genetic recombination technique is purified for a modified major mite allergen Der f 2 wherein both the cysteine residues at 8-position and 119-position in Der f 2 are replaced with serine residues but the present invention should not be construed to be limited thereto.
  • a gene fragment was constructed in which a gene fragment (C8/119S) of a modified major mite allergen (a modified major mite allergen Der f 2 wherein both the cysteine residues at 8-position and 119-position in Der f 2 are replaced with serine residues) was bound downstream of Trp promoter as described below.
  • Trp promoter A gene fragment containing Trp promoter was prepared according to the method reported by Ikehara et al. (Proc. Natl. Acad. Sci. USA, Vol. 81, pp. 5956-5960, 1984). To the 5′ and 3′ ends of the resulting tryptophan promoter gene fragment were bound EcoRI linkers (TaKaRa) and the obtained gene fragment was inserted at the EcoRI site of pBR322 to prepare a recombinant vector pW.
  • a nucleic acid fragment containing a modified major mite allergen gene (C8/119S) was obtained by PCR using as a template a plasmid pFLT11-C8/119S (Japanese Patent Publication No. 253851/1994) bearing said modified major mite allergen gene, a synthetic primer containing at its 5′ end restriction enzyme site NspV (SEQ ID NO: 1) and a synthetic primer containing at its 3′ end restriction enzyme site NruI (SEQ ID NO: 2).
  • replication origin from pBR322 contained in pW11-C8/119S was replaced with that from pUC18.
  • Plasmid pUC18 was completely digested with restriction enzymes PvuI and PvuII to obtain a gene fragment containing a desired replication origin.
  • the plasmid pW11-C8/119S was completely digested with NdeI and, after filling the cohesive ends, completely digested with PvuI to obtain a nucleic acid fragment containing the modified major mite allergen gene (C8/119S).
  • the thus prepared two nucleic acid fragments were linked together with T4 ligase to prepare an expression plasmid pWU11-C8/119S ( FIG. 1 ).
  • E. coli strain HB101 was transformed with the obtained expression plasmid pWU11-C8/119S to obtain recombinant E. coli strain pWU11-C8/119S/HB101, which was used as a strain for producing the desired modified major mite allergen and stocked in glycerol.
  • the culture (about 300 L) was concentrated to about 100 L using MF membrane (Microza; ASAHIKASEI) to recover the E. coli cells.
  • the recovered E. coli cells were diluted 4-fold with deionized water and then concentrated to about 100 L with the MF membrane.
  • the procedure of dilution with deionized water and concentration with the MF membrane was repeated three times in total to remove any contaminating culture components.
  • the E. coli cells were further diluted once with 20 mM Tris buffer at pH 8.5 followed by concentration and buffer exchange. To the resulting cells was added lysozyme at a final concentration of 0.6 g/L. After stirring for 30 minutes, the mixture was transferred to a low-temperature workroom (10° C.
  • the lysozyme solution was subject to French Press (GAULIN CORPORATION) until vanishing of viscosity to disrupt the cells. Due to exothermal reaction when the cells are disrupted, the solution was cooled to 18° C. or less with a heat exchanger. The solution of cell disruption was then subject to three repetitions of the procedures of dilution with deionized water to 400 L and concentration with MF membrane to 100 L so as to remove the cellular components. The concentrated solution of inclusion bodies was centrifuged at 3,000 rpm for 3 hours to precipitate and recover inclusion bodies. The recovered inclusion bodies were measured to weigh 2.5 kg as a wet weight.
  • the refolding reaction was quenched by titration of the above solution to pH 7 with 30% acetic acid.
  • the solution was concentrated to about 10 L with ultrafiltration membrane of fractionation M. W. of 10,000 (Sartorius).
  • To the resultant concentrate was added sodium chloride at a final concentration of 50 mM.
  • the mixture was adjusted to pH 8.5 by titration with a 5N aqueous solution of sodium hydroxide. Insoluble material was removed from the mixture with a filter of ⁇ 0.45 ⁇ m (Sartorius).
  • a column of ⁇ 14 cm (Amicon) was charged with 2 L of DEAE-TOYOPEARL 650M (Tosoh Corporation) and equilibrated with 20 mM Tris buffer at pH 8.5 containing 50 mM sodium chloride.
  • the refolding solution was passed through the column and about 10 L of effluent fractions were recovered.
  • a flow rate was set at 60 cm/h or less. This procedure could remove most of contaminating proteins.
  • the recovered effluent fractions were, after buffer exchange with 20 mM phosphate buffer at pH 7.2 containing 3 M sodium chloride, were filtered through a filter of ⁇ 0.45 ⁇ m.
  • a column of ⁇ 14 cm (Amicon) was charged with 1 L of QAE-TOYOPEARL 550C (Tosoh Corporation) and equilibrated with 20 mM Tris buffer at pH 8.5 containing 2 M urea. Then, the above filtrate solution was passed through the column to let a modified major mite allergen adsorbed to the column. After thoroughly washing the column with the same buffer as used for equilibrium, the modified major mite allergen was eluted with a linear gradient of sodium chloride from 0 to 100 mM (20 column volumes) to recover about 3 L of effluent fractions. A flow rate was set at 60 cm/h or less.
  • the effluent fractions containing the modified major mite allergen were dialyzed to 10 mM phosphate buffer (PBS) at pH 7.2 containing 140 mM sodium chloride and aseptically filtered through a filter of ⁇ 0.22 ⁇ m (Millipore) to obtain a solution of a purified modified major mite allergen (about 4 L, about 500 ⁇ g/ml; Lot Nos.: SF-01, FP-020 and FP-021).
  • a modified major mite allergen was detected with Western blotting.
  • Samples were diluted to an appropriate concentration with water for injection and, under non-reductive condition and after reduction with 2-mercaptoethanol, added to SDS-polyacrylamide gel (Funakoshi Co., Ltd.) for electrophoresis.
  • the electrophoretic gel was immersed in a Trans electrophoresis buffer (10 mM CAPS containing 10% methanol) for 5 minutes and then the proteins in the gel were transferred to PVDF membrane with Trans Western electrophoresis transfer devise. After transfer, the PVDF membrane was immersed in 10 mM Tris buffer containing 2% bovine serum albumin, 0.1% Tween 20 and 0.5 M sodium chloride for blocking at 37° C. for 2 hours.
  • TNT buffer 10 mM Tris buffer containing 0.1% Tween 20 and 0.5 M sodium chloride
  • PBST PBS containing 0.05% Tween 20
  • each 200 ⁇ l of PBS containing 1% bovine serum albumin were added to the plate for blocking at 37° C. for 1 hour.
  • the plate was added with each 100 ⁇ l of a standard solution and sample solutions as appropriately diluted and was left to stand at 37° C. for 2 hours.
  • the plate After washing the plate three times in total with PBST, the plate was added with each 100 ⁇ l of a rabbit anti-C8/119S polyclonal antibody diluted to 2,000-fold and was left to stand at 37° C. for 1 hour. After washing the plate three times in total with PBST, the plate was added with each 100 ⁇ l of a donkey anti-rabbit IgG antibody labeled with horseradish peroxidase and was left to stand at 37° C. for 1 hour. After washing the plate three times in total with PBST, the plate was added with each 100 ⁇ l of TMB solution (Sigma) for reaction for 30 minutes with shielding of light. The reaction was quenched by adding each 100 ⁇ l of 1N sulfuric acid and absorbance at 450 nm was measured to calculate an amount of the modified major mite allergen. The results are shown in Table 1.
  • ELISA plate (Nunc) was coated with 10 ⁇ g/ml of guinea pig anti-host-derived contaminating component polyclonal antibody at 4° C. overnight. After washing the plate three times in total with PBS containing 0.05% Tween 20 (PBST), each 200 ⁇ l of Block Ace (Dainippon Shiyaku) were added to the plate for blocking at 37° C. for 1 hour. After washing the plate three times in total with PBST, the plate was added with each 100 ⁇ l of sample solutions of modified major mite allergen from the final purification step and was left to stand at 37° C. for 2 hours.
  • PBST PBS containing 0.05% Tween 20
  • the plate After washing the plate three times in total with PBST, the plate was added with each 100 ⁇ l of a rabbit anti-host-derived contaminating component polyclonal antibody (1 ⁇ g/ml) and was left to stand at 37° C. for 1 hour. After washing the plate three times in total with PBST, the plate was added with each 100 ⁇ l of a donkey anti-rabbit IgG antibody labeled with horseradish peroxidase and was left to stand at 37° C. for 1 hour. After washing the plate three times in total with PBST, the plate was added with each 100 ⁇ l of TMB solution (Sigma) for reaction for 10 minutes with shielding of light.
  • TMB solution Sigma
  • the reaction was quenched by adding each 100 ⁇ l of 0.3N sulfuric acid and absorbance at 450 nm was measured to calculate an amount of the host-derived contaminating component.
  • a content of the host-derived contaminating component is shown in Table 2.
  • a detection limit in this ELISA system was 0.004%.
  • the contaminating proteins contained in the modified major mite allergen were analyzed by reducing the samples from each purification step with 2-mercaptoethanol, electrophoresing an amount equivalent to 2 ⁇ g of the modified major mite allergen on polyacrylamide gel (Funakoshi Co., Ltd.), and developing with Coomassie Brilliant Blue.
  • the conditions of electrophoresis were as described in the instructions attached to the device. It could be confirmed that the more the purification steps advanced the less bands of contaminating proteins appeared ( FIG. 5 ).
  • the samples from the final purification step were, after non-reductive or reductive treatment, subject to SDS-PAGE under the same conditions as described above.
  • the modified major mite allergen was confirmed to be present in a band of M.W. of about 15 kD ( FIG. 6 ).
  • Purity of the modified major mite allergen from the final purification step was measured by HPLC.
  • a content of a polymer of the modified major mite allergen was measured by a gel filtration chromatography and a content of the modified major mite allergen with distinct steric structure due to wrong S—S bond formation etc. was measured by a reversed phase chromatography.
  • An analytic column used was G3000SW XL (Tosoh Corporation). A 60% acetonitrile solution containing 0.1% TFA was used as a mobile phase. A flow rate was 1 ml/min. and analytical time was set for 20 minutes. Each 100 ⁇ l of samples containing about 500 ⁇ g/ml of the modified major mite allergen were used for analysis. Twelve minutes after initiation of the analysis, solvent-derived peaks began to be detected. Therefore, analysis was within 12 minutes and a relative content of a polymer of the modified major mite allergen was calculated from an integral for 12 minutes. A content of a polymer of the modified major mite allergen was found to be less than a detection limit ( FIG. 7 ). A detection limit of the gel filtration chromatography was 0.005%.
  • An analytic column used was CAPCELL PAK C1 (Shiseido Company, Limited).
  • As a mobile phase 0.1% TFA for A buffer and a 70% acetonitrile solution containing 0.1% TFA for B buffer were used.
  • a flow rate was 1 ml/min. and a linear gradient of a mixed ratio of B buffer from 28.6% to 50% in 60 minutes was used.
  • Each 100 ⁇ l of samples containing about 500 ⁇ g/ml of the modified major mite allergen were used for analysis. Immediate after initiation of the analysis, noise was detected. Therefore, analysis was from 13 minutes up till 60 minutes and a relative content of a major peak was calculated from an integral during this period.
  • a relative content of the modified major mite allergen of interest was found to be 90% or more, in other words, a content of the modified major mite allergen with distinct steric structure was 10% or less ( FIG. 8 ).
  • a detection limit of the reversed phase chromatography was 0.03%.
  • An endotoxin content of the modified major mite allergen from the final purification step was measured.
  • a reagent kit manufactured by SEIKAGAKU CORPORATION was used and a measurement was made as described in the instructions attached to the reagent.
  • the results are shown in Table 3.
  • An endotoxin content of a solution of the modified major mite allergen (500 ⁇ g/ml) was less than 0.25 EU/ml, a quality standard for water for injection (Japanese Pharmacopoeia, 14th edition).
  • a detection limit of the endotoxin text was 0.002 EU/ml.
  • the modified major mite allergen from the final purification step (Lot Nos.: SF-01, FP-020, FP-021) was diluted with water for injection to 150 ⁇ g/ml and was subject to isoelectric focusing with First System (Pharmacia). Isoelectric focusing was performed as described in the instruction manual attached to the device and the gel after electrophoresis was stained with silver. As a result, it was estimated that the purified modified major mite allergen had an isoelectric point of pI 6.6 to 7.2 ( FIG. 9 ).
  • the modified major mite allergen from the final purification step (Lot Nos.: FP-020, FP-021) and the conventional purified Der f 2 (Asahi Beer Pharmaceuticals) were diluted with a saline to 200 ⁇ g/ml and was subject to SDS-polyacrylamide gel electrophoresis by adding each 1 ⁇ g per lane.
  • the electrophoresed gel was stained with a silver stain kit (Daiichi Pure Chemicals Co., Ltd.) ( FIG. 10 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Laminated Bodies (AREA)
US10/555,883 2003-05-07 2004-04-14 Method for purifying modified major mite allergen Expired - Fee Related US7667009B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003128610 2003-05-07
JP2003-128610 2003-05-07
PCT/JP2004/005315 WO2004099406A1 (ja) 2003-05-07 2004-04-14 改変ダニ主要アレルゲンの精製方法

Publications (2)

Publication Number Publication Date
US20080113424A1 US20080113424A1 (en) 2008-05-15
US7667009B2 true US7667009B2 (en) 2010-02-23

Family

ID=33432048

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/555,883 Expired - Fee Related US7667009B2 (en) 2003-05-07 2004-04-14 Method for purifying modified major mite allergen

Country Status (6)

Country Link
US (1) US7667009B2 (de)
EP (1) EP1621615B1 (de)
JP (1) JP4573772B2 (de)
AT (1) ATE461278T1 (de)
DE (1) DE602004026048D1 (de)
WO (1) WO2004099406A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2593778C3 (ru) * 2010-06-03 2020-12-21 Альк-Абелло А/С Фармацевтический продукт, содержащий экстракт(ы) аллергена клещей, и способ его получения
AU2015239770B2 (en) 2014-03-31 2020-07-02 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses thereof
AU2016333474A1 (en) * 2015-09-30 2018-03-22 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
CN105769775A (zh) * 2016-03-24 2016-07-20 浙江华海药业股份有限公司 一种注射用阿扎胞苷的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06253851A (ja) 1993-03-04 1994-09-13 Asahi Breweries Ltd 改変したダニ主要アレルゲン及びその製造方法
WO1996030539A1 (fr) 1995-03-28 1996-10-03 Asahi Breweries, Ltd. Allergene d'acarien obtenu grace au genie genetique et son procede de fabrication
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
JP2001231563A (ja) 2000-02-18 2001-08-28 Asahi Breweries Ltd 改変したダニアレルゲン（システイン変異体）及びその製造方法
JP2001231562A (ja) 2000-02-18 2001-08-28 Asahi Breweries Ltd 改変したダニアレルゲン（プロリン変異体）及びその製造方法
US20020054881A1 (en) 2000-09-12 2002-05-09 Monica Sturaro Variants of allergenic proteins of the group 2 of dermatophagoides
US6632425B1 (en) * 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06253851A (ja) 1993-03-04 1994-09-13 Asahi Breweries Ltd 改変したダニ主要アレルゲン及びその製造方法
WO1996030539A1 (fr) 1995-03-28 1996-10-03 Asahi Breweries, Ltd. Allergene d'acarien obtenu grace au genie genetique et son procede de fabrication
EP0819763A1 (de) 1995-03-28 1998-01-21 Asahi Breweries, Ltd. Gentechnologisch hergestelltes milbenantigen und herstellungsverfahren
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
US6632425B1 (en) * 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
US20040024186A1 (en) * 1997-03-20 2004-02-05 Human Genome Sciences, Inc. Method of purifying protein from inclusion bodies
JP2001231563A (ja) 2000-02-18 2001-08-28 Asahi Breweries Ltd 改変したダニアレルゲン（システイン変異体）及びその製造方法
JP2001231562A (ja) 2000-02-18 2001-08-28 Asahi Breweries Ltd 改変したダニアレルゲン（プロリン変異体）及びその製造方法
US20020054881A1 (en) 2000-09-12 2002-05-09 Monica Sturaro Variants of allergenic proteins of the group 2 of dermatophagoides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Shin Seikagaku Jikken Koza 1 Tanpakushitsu I-Bunri Seisei Seishitsu" (New Lecture on Biochemical Experiment 1: Isolation, Purification and Property), edited by The Japanese Biochemical Society, published on Feb. 26, 1990, pp. 169-177 and 184-194.
"Tanpakushitsu Kogaku" (Protein Engineering), edited by Kin'ichiro Miura et al, published on Jul. 16, 1988, p. 118.
Mukhopadhyay et al. 'Inclusion bodies and purfication of proteins in biologically active forms.' Adv. Biochem. Eng. 56:61-109, 1997. *
Thomas A.E. Platts-Mills et al; "Dust mites: Immunology, allergic disease, and environmental control"; The Journal of Allergy and Clinical Immunology; vol. 80, pp. 755-775, 1987.
Toshifumi Yuuki et al; "Cloning and Sequencing of cDNAs corresponding to mite major allergen"; Japanese J. Allergology, vol. 39, pp. 557-561, 1990.
Toshiro Takai et al; "Engineering of the Major House Dust Mite Allergen DER f 2 for Allergen-Specific Immunotherapy"; Nature Biotechnology; Aug. 15, 1997; pp. 754-758 ISSN: 1087-0156; vol. 15; Publishing Group, New York, NY US.

Also Published As

Publication number Publication date
JP4573772B2 (ja) 2010-11-04
JPWO2004099406A1 (ja) 2006-07-13
EP1621615B1 (de) 2010-03-17
WO2004099406A1 (ja) 2004-11-18
ATE461278T1 (de) 2010-04-15
EP1621615A4 (de) 2007-05-02
US20080113424A1 (en) 2008-05-15
EP1621615A1 (de) 2006-02-01
DE602004026048D1 (de) 2010-04-29

Similar Documents

Publication Publication Date Title
Dulhanty et al. Phosphorylation by cAMP-dependent protein kinase causes a conformational change in the R domain of the cystic fibrosis transmembrane conductance regulator
IE68408B1 (en) Purification of hepatitis proteins
JP2596466B2 (ja) ダニの主要アレルゲンの還伝情報を有するｄｎａおよび該アレルゲンの製造方法
DK175251B1 (da) Renfremstilling af erythropoietin
EP0315650B1 (de) Reinigung von rekombinantem interleukin-1
EP1531160A1 (de) Gewinnung von Hitzeschockproteinen
US7667009B2 (en) Method for purifying modified major mite allergen
Marquardt et al. Human glomerular basement membrane. Selective solubilization with chaotropes and chemical and immunologic characterization of its components
JPS63297A (ja) 遺伝子発現産物の精製法
US9441021B2 (en) Process for the preparation of hypoallergenic major birch pollen allergen rBet v 1
US9127075B2 (en) Analgesic active peptide VGG, preparation and use thereof
US4751078A (en) Process for the purification of gamma interferon
KR101652060B1 (ko) 재조합 닭 전염성 코라이자 백신 및 그 제조방법
CN106632664B (zh) 载脂蛋白ii/i及其制备方法、生物学功能及应用
Jones et al. Purification of C8 and C9 from rat serum
EP2617829A1 (de) Synthetisches gen zur expression von sm-14 in pichia pastoris, verfahren zur herstellung und reinigung von sm-14 und verwendung davon als impfstoff und diagnosemedium
RU2323942C2 (ru) ВАРИАНТЫ ОСНОВНОГО АЛЛЕРГЕНА Phl p 1 ИЗ ТИМОФЕЕВКИ ЛУГОВОЙ
TW200906433A (en) Therapeutic agent for acute hepatitis or prophylactic and/or therapeutic agent for fulminant hepatitis
DK171419B1 (da) Mikrobielt fremstillet humant Interleukin-1, fremgangsmåder til fremstilling deraf samt farmaceutiske preparater indeholdende dette, og dets anvendelse i behandling og profylakse
WO1990005181A1 (de) REINIGUNG VON Cu/Zn-SUPEROXIDDISMUTASE
Mozetič-Francky et al. High-yield expression and purification of recombinant human macrophage migration inhibitory factor
EP0868507B1 (de) Verfahren zur reinigung der urease aus helicobacter pylori
US10081660B2 (en) Polynucleotide, polypeptide with immunosuppressive activity, expression cassette, expression vector, host cell, pharmaceutical composition, methods for producing a polypeptide with immunosuppressive activity and for preventing or treating conditions that require immunosuppression, and use of a polypeptide
上村毅 et al. The Complement System of Carp Cyprinus carpio-VI. Isolation of the Second Component of Complement (C2) from Carp Serum.
Kelly et al. Recombinant expression, purification and characterisation of the HMG domain of human SRY

Legal Events

Date Code Title Description
AS Assignment

Owner name: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOYANAGI, SATOSHI;KAWATSU, KENJIRO;MURAKAMI, TOSHIO;AND OTHERS;REEL/FRAME:020111/0319

Effective date: 20050826

CC Certificate of correction
AS Assignment

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, JAP

Free format text: CHANGE OF NAME;ASSIGNOR:JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE;REEL/FRAME:029636/0944

Effective date: 20100401

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20180223